https://apnews.com/839bf6a7c857b25df04078402b4d7b8a

With the U.S. pause of Johnson & Johnson’s COVID-19 vaccine stretched into a second week, authorities are weighing whether to resume the shots the way European regulators decided to -- with warnings of a “very rare” risk.

New guidance is expected late Friday after a government advisory panel deliberates a possible link between J&J’s shot and a handful of vaccine recipients who developed highly unusual blood clots.